Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation

Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis

NCT02555969 ·Status: COMPLETED

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

NCT01728259 ·Status: TERMINATED ·Phase: PHASE1

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

NCT06292780 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

NCT06097832 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

NCT02613182 ·Status: TERMINATED ·Phase: PHASE2

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

NCT01707264 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis

NCT07215494 ·Status: NOT_YET_RECRUITING ·Phase: NA

FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

NCT05978661 ·Status: RECRUITING ·Phase: PHASE1

CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

NCT00091260 ·Status: COMPLETED ·Phase: PHASE2

Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis

NCT00607581 ·Status: COMPLETED ·Phase: PHASE2

Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis

NCT00030381 ·Status: TERMINATED ·Phase: PHASE1

Daratumumab for Patients With Light Chain Amyloidosis

NCT06376214 ·Status: RECRUITING ·Phase: NA

A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

NCT01789242 ·Status: COMPLETED ·Phase: PHASE1

Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)

NCT01142856 ·Status: COMPLETED ·Phase: PHASE1

Study in Subjects With Light Chain (AL) Amyloidosis

NCT03154047 ·Status: TERMINATED ·Phase: PHASE2

The Effect of Diflunisal on Familial Transthyretin Amyloidosis

NCT01432587 ·Status: COMPLETED

A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis

NCT01609283 ·Status: COMPLETED ·Phase: PHASE1

Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)

NCT03268603 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis

NCT01082653 ·Status: SUSPENDED ·Phase: PHASE1

Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy

NCT05167721 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

NCT06455748 ·Status: RECRUITING ·Phase: NA

Mesenchymal Stem Cell Therapy in Multiple System Atrophy

NCT02315027 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis

NCT01222260 ·Status: COMPLETED ·Phase: PHASE2

Quality of Life (QOL) Registry for Patients With AL Amyloidosis

NCT02574676 ·Status: COMPLETED

A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

NCT00890552 ·Status: COMPLETED ·Phase: NA